ArticleJournal of translational medicine2011
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.
Article in Journal of translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.International journal of molecular sciences · 2023Article
- Antitumor Peptide-Based Vaccine in the Limelight.Vaccines · 2022Review
- Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer.Vaccines · 2021Article
- Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition.Histochemistry and cell biology · 2020Article
- Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.Cancer immunology, immunotherapy : CII · 2020Article
- T Cell Dysfunction and Exhaustion in Cancer.Frontiers in cell and developmental biology · 2020Review
- Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8Drug delivery and translational research · 2019Article
- Iron and leukemia: new insights for future treatments.Journal of experimental & clinical cancer research : CR · 2019Review
- Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy.American journal of clinical and experimental urology · 2019Review
- Melanoma antigen family A4 protein produced by transgenic silkworms induces antitumor immune responses.Experimental and therapeutic medicine · 2018Article
- miR-21 modulates the effect of EZH2 on the biological behavior of human lung cancer stem cellsOncotarget · 2017Article
- Review
- IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.Cancer immunology, immunotherapy : CII · 2016Article
- Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma.Scientific reports · 2015Article
- c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.Oncoimmunology · 2015Article
- EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.British journal of cancer · 2013Article
- A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope.Cancer immunology, immunotherapy : CII · 2012Article
- The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma.Neoplasia (New York, N.Y.) · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundT-cell based immunotherapy for lung cancer (LC) could be a promising and novel therapeutic approach. Six-transmembrane epithelial antigen of the prostate (STEAP) and the polycomb group protein enhancer of zeste homolog 2 (EZH2) are highly expressed in LC and since the expression of molecules in normal tissue is significantly lower as compared to tumor cells, these proteins are considered as potential tumor-associated antigens (TAAs) for developing T-cell based immunotherapy.
methodsWe assessed the capacity of predicted CD4 T-cell epitopes from STEAP and EZH2 to induce anti-tumor immune responses to LC cell lines.
resultsOut of several predicted epitopes, two synthetic peptides, STEAP281-296 and EZH295-109, were effective in inducing CD4 T-cell responses that were restricted by HLA-DR1, DR15, or DR53 molecules, indicating that the peptides function as promiscuous T-cell epitopes. Moreover, STEAP281-296 and EZH295-109-reactive T-cells could directly recognize STEAP or EZH2 expressing LC cells in an HLA-DR restricted manner. In addition, some STEAP-reactive T-cells responded to STEAP+ tumor cell lysates presented by autologous dendric cells. Most significantly, both of these peptides were capable of stimulating in vitro T-cell responses in patients with LC.
conclusionsPeptides STEAP281-296 and EZH295-109 function as strong CD4 T-cell epitopes that can elicit effective anti-tumor T-cell responses against STEAP or EZH2 expressing LC. These observations may facilitate the translation of T-cell based immunotherapy into the clinic for the treatment of LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.